Trial Profile
A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of Severe Pulmonary Arterial Hypertension: Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study (IMPRES)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Oct 2014
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms IMPRES
- Sponsors Novartis Pharmaceuticals Corporation
- 10 May 2014 New trial record
- 30 Apr 2012
- 01 Dec 2010